TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07227350: L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Sponsor: Philogen S.p.A. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,049,200

Rescue Site Savings

+$2,032,800

Unlock Full NCT07227350 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227350 Rescue Dossier →